Article Text

Download PDFPDF
Lysis Timer: a new sensitive tool to diagnose hyperfibrinolysis in liver transplantation
  1. Stéphanie Roullet1,2,
  2. Sylvie Labrouche3,4,
  3. Christine Mouton5,
  4. Alice Quinart6,
  5. Karine Nouette-Gaulain1,2,
  6. Christophe Laurent7,
  7. Geneviève Freyburger4
  1. 1 CHU Bordeaux, Service d’Anesthésie-Réanimation Pellegrin, Bordeaux, France
  2. 2 Université de Bordeaux, INSERM U 12-11, Maladies rares: Génétique et Métabolisme, Bordeaux, France
  3. 3 CHU Bordeaux, Laboratoire d’Hématologie – PTRR, Hôpital Pellegrin, Bordeaux, France
  4. 4 Université de Bordeaux, INSERM U 10-34, Biologie des Maladies Cardio-Vasculaires, Pessac, France
  5. 5 CHU Bordeaux, Service d’Hématologie Biologique, Bordeaux, France
  6. 6 CHU Bordeaux, Service d’Anesthésie-Réanimation Sud, Pessac, France
  7. 7 CHU Bordeaux, Service de Chirurgie Hépato-biliaire et Transplantation Hépatique, Pessac, France
  1. Correspondence to Dr Stéphanie Roullet, Anesthésie-réanimation uro-vasculaire et transplantation rénale, Service Anesthésie Réanimation Pellegrin - Centre Hospitalier Universitaire de Bordeaux, Bordeaux 33076, France; stephanie.roullet{at}


Aims Diagnosis of hyperfibrinolysis in orthotopic liver transplantation (OLT) remains challenging. Euglobulin clot lysis time (ECLT) is not adapted to clinical situations. ROTEM is specific but seldom sensitive to hyperfibrinolysis. The Lysis Timer assesses ‘Global Fibrinolytic Capacity’ in citrated plasma (GFC/LT). GFC/LT associates reagents for in vitro triggering of the clot (thrombin and calcium) and its lysis (tissue-plasminogenactivator (t-PA)), turbidity signal acquisition by the Lysis Timer, and dedicated software converting the digital signal into an optical curve. A visual check of the curves was systematic to ascertain the lysis time values calculated by the software. The primary aim of this prospective observational study was to evaluate the ability of GFC/LT to recognise hyperfibrinolysis during OLT. The secondary aim was to compare its results with ROTEM maximum lysis (EXTEM ML) and with standard laboratory tests.

Methods Thirty consecutive adult patients undergoing OLT were included (NCT03012633). Standard laboratory tests, ROTEM, GFC/LT, ECLT and fibrinolysis parameters were assayed at five sample times.

Results GFC/LT was correlated with ECLT, plasmin activator inhibitor 1 antigen and activity and t-PA activity (r=0.490, 0.681, 0.643 and –0.359, respectively). Hyperfibrinolysis was defined as ECLT ≤60 min. Receiver operating characteristic curve analysis showed that GFC/LT with a threshold of 31 min detected hyperfibrinolysis with a sensitivity of 0.88 (95% CI 0.73 to 0.96), a specificity of 0.68 (95% CI 0.56 to 0.78) and an area under the curve (AUC) of 0.85 (95% CI 0.74 to 0.94). EXTEM ML >12% did not detect hyperfibrinolysis (sensitivity 0.38 (95% CI 0.24 to 0.55), specificity 0.95 (95% CI 0.86 to 0.99) and AUC 0.60 (95% CI 0.46 to 0.75)).

Conclusions GFC/LT recognised hyperfibrinolysis during OLT with a significant agreement with the other tests of fibrinolysis.

Trial registration number NCT03012633.

  • euglobulin clot lysis time
  • global fibrinolytic capacity
  • principal component analysis
  • thromboelastometry

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Handling editor Mary Frances McMullin.

  • Contributors SR conceived the study, included patients, provided samples, performed laboratory plasma assays, analysed the results, made the figures and wrote the manuscript. SL and CM performed whole blood experiments and laboratory plasma assays. AQ and CL included patients and provided samples. KN-G participated in data analysis and provided critical revisions to the manuscript. GF conceived the study, analysed the results, made the figures and wrote the manuscript. The final version was approved by all authors.

  • Funding This study was supported by institutional funding.

  • Competing interests None declared.

  • Patient consent Not required.

  • Ethics approval This study was approved by the CCP Sud-Ouest and Outremer III, France (nº DC 2016/142).

  • Provenance and peer review Not commissioned; externally peer reviewed.